Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Breast 1

Conditions

Breast Neoplasms 3Triple Negative Breast Neoplasms 2Ovarian Neoplasms 1Fallopian Tube Neoplasms 1Estrogen Receptor Positive Breast Cancer 1Advanced Metastatic Breast Cancer 1

Interventions

pembrolizumab 8Carboplatin 6Cyclophosphamide 5veliparib 4olaparib 4Magnetic Resonance Spectroscopy 4liposomal doxorubicin 3Taxes 3Paclitaxel 3Gene Expression Profiling 3Gemcitabine 3palbociclib 2niraparib 2fludarabine 2durvalumab 2Temozolomide 2Specimen Handling 2Psychiatric Rehabilitation 2Polymerase Chain Reaction 2Oxaliplatin 2Nivolumab 2Leucovorin 2Interleukin-2 2Fulvestrant 2Fluorouracil 2Early Intervention, Educational 2Drug Therapy 2Doxorubicin 2Biopsy 2130-nm albumin-bound paclitaxel 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Fallopian Tube Neoplasms × vistusertib × Breast × Clear all
NCT02208375 2025-12-31

mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian

M.D. Anderson Cancer Center

Phase 1 Active not recruiting
159 enrolled
BreastGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡